Chemo-radiotherapy versus radiotherapy alone in the pre-operative treatment of resectable rectal cancer

Laurence Goethals, K. Haustermans, C. Perneel, B. Bussels, A. D'Hoore, K. Geboes, N. Ectors, E. Van Cutsem, W. Van den Bogaert, F. Penninckx

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: To determine the differences in downstaging, local control (LC), disease free survival (DFS) and overall survival (OS) between combined pre-operative chemoradiation and pre-operative radiotherapy alone in the treatment of resectable rectal cancer. Methods: One hundred and ten patients who underwent pre-operative radiotherapy or chemo-radiotherapy were reviewed. Fifty-seven patients were treated with radiotherapy (30 Gy/3 Gy) alone and 53 patients with chemo-radiotherapy (bolus 5FU+45 Gy/1.8 Gy). The median interval between the end of neo-adjuvant treatment and surgery was 28 and 46 days for the patients treated with radiotherapy alone and chemo-radiotherapy. Results: The groups were homogeneously distributed for all characteristics except for cN-stage with more clinically node positive patients in the combined modality treatment group (47 vs 73%). A significant downstaging for tumour and/or lymph node status was observed in both groups. More ypT0-x-is were observed after chemoradiation than after radiotherapy alone (26 vs 7%; p=0.02). The local control rate at 3 years was 94% for both groups. DFS after radiation and chemoradiation was comparable with a 3-year DFS of 83 and 88%, respectively. Conclusion: Both pre-operative schemes have similar outcomes concerning DFS, OS and LC. Tumour downstaging is associated with improved survival.

Original languageEnglish
Pages (from-to)969-976
Number of pages8
JournalEuropean Journal of Surgical Oncology
Volume31
Issue number9
DOIs
Publication statusPublished - Nov 2005

Keywords

  • Combined modality
  • Pre-operative radiotherapy
  • Rectal cancer

Fingerprint

Dive into the research topics of 'Chemo-radiotherapy versus radiotherapy alone in the pre-operative treatment of resectable rectal cancer'. Together they form a unique fingerprint.

Cite this